Noncoding variants at human chromosome 9p21 near CDKN2A and CDKN2B are associated with type 2 diabetes 1-4 , myocardial infarction 5-7 , aneurysm 8 , vertical cup disc ratio 9 and at least five cancers 10-16 . Here we compare approaches to more comprehensively assess genetic variation in the region. We carried out targeted sequencing at high coverage in 47 individuals and compared the results to pilot data from the 1000 Genomes Project. We imputed variants into type 2 diabetes and myocardial infarction cohorts directly from targeted sequencing, from a genotyped reference panel derived from sequencing and from 1000 Genomes Project low-coverage data. Polymorphisms with frequency >5% were captured well by all strategies. Imputation of intermediatefrequency polymorphisms required a higher density of tag SNPs in disease samples than is available on first-generation genome-wide association study (GWAS) arrays. Our association analyses identified more comprehensive sets of variants showing equivalent statistical association with type 2 diabetes or myocardial infarction, but did not identify stronger associations than the original GWAS signals.
After the identification of a disease-associated region by GWAS, comprehensive study of sequence variation in the region is required to identify the full set of variants that might explain the association signal. Because GWAS arrays incompletely capture DNA variation in each region, it has been hypothesized that causal variants partially captured by linkage disequilibrium-for example, owing to location near recombination hotspots or low minor allele frequency-might, if directly tested, show stronger association with phenotype than the tag SNPs used in GWAS. In particular, because HapMap and GWAS arrays contain primarily variants with minor allele frequency (MAF) >5%, first-generation GWAS studies have not tested polymorphisms of somewhat lower frequency that might have larger effects on disease risk. Finally, even in regions in which the true association signal is well captured by linkage disequilibrium with array SNPs, enumeration of all associated variants is a necessary prerequisite for functional experiments to identify causal variant(s). Thus, an important next step after GWAS is to assemble a more complete catalog of variation present in an associated region and to test it for association with the phenotype of interest.
With the advent of next-generation sequencing and the emergence of data from the 1000 Genomes Project, investigators must choose among (or combine) multiple strategies for creating and testing a reference panel of polymorphic sites. We resequenced ~240 kilobases (kb) at chromosome 9p21 (chr9:21936711-22176221, hg18) spanning the type 2 diabetes and myocardial infarction associations in 47 unrelated individuals from the HapMap Centre d'Etude du Polymorphisme Humain from Utah (CEU) 17 Comparing strategies to fine-map the association of common SNPs at chromosome 9p21 with type 2 diabetes and myocardial infarction 8 0 2 VOLUME 43 | NUMBER 8 | AUGUST 2011 Nature GeNetics l e t t e r S Kit 18, 19 , that includes methods to empirically recalibrate Illumina base quality scores, a Bayesian framework to call SNPs, local realignment to identify insertions and deletions (and remove clusters of falsepositive SNPs) and filters to remove false-positive SNP calls on the basis of discrepancy between forward and reverse strand reads.
Using this targeted sequencing, we identified 635 high-confidence SNPs at chromosome 9p21 (4,463 SNPs across the six regions; Supplementary Table 3 and Supplementary Fig. 6 ; SNPs are available in dbSNP). We evaluated sensitivity against HapMap II 17 and the high-coverage Pilot 2 data from the 1000 Genomes Project 20 (Supplementary Note). At sites in overlapping samples with ≥10× read coverage (70% of the region), sensitivity was 99% for HapMap variants and 97% for variants found in 1000 Genomes Pilot 2 ( Supplementary Fig. 7a-c) . To evaluate specificity, we genotyped 257 sites found at chromosome 9p21 but not previously genotyped in HapMap (Supplementary Fig. 7d,e) . Overall, 96% of variants seen more than once in sequencing were validated in the genotyping data (Supplementary Table 4) .
We compared these variants to those discovered in the lowcoverage Pilot 1 of the 1000 Genomes Project 20 , limiting comparison to 32 CEU individuals studied in both projects. Across the six regions, both projects identified similar numbers of variants: 3,897 SNPs in the high-coverage targeted sequencing compared with 4,043 in 1000 Genomes Pilot 1. However, the variants found only partially overlapped. Of variants seen in the high-coverage targeted sequencing, 22% were missed by 1000 Genomes Pilot 1 (Fig. 1) , nearly all of which were rare: 72% of these sites were singletons and 12% were seen twice ( Fig. 1 and Table 1 ). Conversely, Pilot 1 successfully identified 97% of SNPs seen more than five times in high-coverage sequencing ( Table 1) . Of variants identified in Pilot 1 but not in targeted sequencing (n = 998), nearly all were sites at which target capture did not achieve high coverage: 65% of these sites had zero coverage. Thus, targeted capture and lowpass whole-genome sequencing had distinct and nonoverlapping failure modes.
We evaluated methods for testing these variants for association with disease via linkage disequilibrium and haplotype-based imputation. First, we genotyped SNPs found in targeted resequencing of chromosome 9p21 in 168 individuals (56 parent offspring trios) from the HapMap extended CEU population 21 (Supplementary Note). We used the imputation engine MACH 22, 23 to impute variants from this reference panel into 1,000 type 2 diabetes cases and 1,048 controls from the Diabetes Genetics Initiative (DGI) cohort 1 and 1,274 myocardial infarction cases and 1,407 controls from the Myocardial Infarction Genetics (MIGen) Consortium cohort 6 , each of which were previously genotyped on Affymetrix GWAS arrays (Supplementary Note).
We compared the results of imputation with this augmented reference panel (n = 464 variants; Supplementary Table 5) to those obtained when imputing from HapMap II alone (n = 238 variants in 30 parent-offspring trios). The addition of genotype data for a more complete collection of common variants provided imputation data for a much larger number of SNPs than was possible with HapMap II, which contains only 50-60% of common variants (Fig. 2a,b and Supplementary Fig. 8a,b) . However, even with the augmented reference panel, the tag SNP density characteristic of the first-generation GWAS arrays on which our disease samples were typed allowed only 80% of common (MAF > 5%) variants to be captured (either directly typed or imputed with a MACH-estimated r 2 ≥ 0.8). Moreover, only a small percentage of intermediate-frequency variation (MAF 2-5%) was imputed with an estimated r 2 greater than this stringent threshold (Fig. 2c,d and Supplementary Fig. 8c,d) .
To evaluate the impact of tag SNP density on imputation performance, we increased the number of tags across the region to ~1 SNP per 1.5 kb (previous density was ~1 SNP per 5 kb in type 2 diabetes samples and ~1 SNP per 3 kb in myocardial infarction samples) in the type 2 diabetes and myocardial infarction cohorts (Supplementary Note). With this increased density of tag SNPs, nearly all common variants (~98%) were captured with r 2 ≥ 0.8 in disease samples. Moreover, performance for intermediate-frequency variants was markedly improved, rising from 2% to 75% with r 2 ≥ 0.8 ( Fig. 2e,f and Supplementary Fig. 8e,f) . This result was not specific to the Affymetrix GWAS arrays, as we observed a similar improvement in imputation ability upon addition of tag SNPs using several other GWAS arrays (Supplementary Fig. 9 ).
We next compared different reference panels, imputing in each case into disease samples with the higher tag SNP density. The reference panels were the genotyped reference panel of 168 individuals described above (112 unrelated individuals), the targeted sequencing data (47 individuals, without genotyping and expansion into a larger sample set) and 1000 Genomes Pilot 1 (55 individuals). We considered both the fraction of variants in each reference panel successfully imputed (which is related to the quality and completeness of SNP genotypes and to the size of the reference panel) and the fraction of l e t t e r S all variation captured (which also depends on the proportion of all known SNPs represented in the reference panel). The union of the three reference panels contained 582 variants (Fig. 3a) . Each panel was partially incomplete because of genotyping assay failure in the genotyped panel (14% of SNPs missing), sample size and low coverage in 1000 Genomes (16% of SNPs missing) and sample size and gaps in coverage in the targeted sequencing (19% of SNPs missing). For common variants, there was little difference in bulk performance among the reference panels. Considering only SNPs contained in each reference panel (Fig. 3b) , the genotyped panel had the highest proportion of variants imputed well. However, when all variation is considered (Fig. 3c) , a lower proportion of common l e t t e r S variation was captured by imputing from the genotyped reference panel, owing to the fact that some SNPs were missing in this panel because they failed assay design or quality control. Notably, the freely available 1000 Genomes and costly sequencing strategies performed equivalently for these common variants.
For intermediate-frequency variants, there were more pronounced differences among the panels (Fig. 3b,c) . These variants were best imputed from the genotyped reference panel (Fig. 3b) , which was the largest and also contained trio information. This was true even when all variation was considered (Fig. 3c) , suggesting that the improved imputation quality from genotype data and increased sample size offset the loss of variants in this panel owing to genotyping failure. Comparing the high-coverage resequencing and 1000 Genomes reference panels, lower-frequency variants were better imputed from the high-coverage resequencing data both when considering only the SNPs within each reference panel (Fig. 3b) and when considering the overall proportion of low-frequency variants captured by imputation from each reference panel (Fig. 3c) . This is consistent with the fact that the low-coverage 1000 Genomes Pilot 1 data are less complete and accurate for lower-frequency variants 20 .
We tested variants for association with type 2 diabetes and myocardial infarction using imputation from all three reference panels to maximize the number of variants captured (Supplementary Note). Overall, we have captured 461 of the 582 polymorphic variants observed across all three reference panels in our type 2 diabetes and myocardial infarction samples with a MACH-estimated r 2 ≥ 0.8. This represents ~92% of all known common variants and ~52% of intermediate-frequency variants (at a MACH-estimated r 2 of 0.5, these figures are 98% of common variants and 83% of intermediatefrequency variants). In comparison, only 176 of the 582 variants were previously captured by imputation from HapMap. Despite testing many additional SNPs in partial linkage disequilibrium with the index GWAS hits and at allele frequencies not well captured by firstgeneration GWAS arrays and HapMap, we found no example of a SNP with stronger association with type 2 diabetes or myocardial infarction than the initial GWAS signals. However, we identified multiple additional variants in strong linkage disequilibrium with the GWAS hits that might underlie each association. We observed the three-tiered haplotypic association with type 2 diabetes first reported by the Wellcome Trust Case Control Consortium with protective, risk and neutral haplotypes ( Table 2 ). The protective alleles of the GWAS SNP (rs10811661) and nine other SNPs in strong linkage disequilibrium with this variant tag the protective haplotype (Fig. 4a and Supplementary Table 6) . Notably, no single SNP identified so far marks the risk haplotype. Association analyses for myocardial infarction identified seven SNPs in linkage disequilibrium with each other and with equivalent evidence for association (P < 10 -4 ) and 54 additional SNPs with only slightly less evidence for association (P < 10 -3 ) (Fig. 4b and Supplementary Table 6 ). Deletion of the myocardial infarction-associated region in mice alters regulation of CDKN2A and CDKN2B 24 , and two of the associated SNPs disrupt a STAT1-binding site 25 . Notably, in addition to the SNPs disrupting the STAT1 site, there are other variants with equivalent myocardial infarction association and with putative functional annotations, including variants overlapping exons of the noncoding transcript CDKN2B-AS1, highly conserved regions and predicted, conserved transcription factor-binding sites (Supplementary Table 6 ).
This study is limited by the investigation of a single region (albeit one with at least eight different disease associations), the early nature of the sequencing data analyzed, the small number of samples sequenced in SNP discovery and the sample size of our disease cohorts. Nonetheless, our observations of the strengths and weaknesses of different methods for fine-mapping GWAS signals may have general relevance. We find that targeted sequencing provides high sensitivity for lower-frequency variants but has gaps in coverage, whereas the 1000 Genomes Pilot 1 resource offers more even coverage at lower depth, and is already sufficient to capture most SNPs with frequency >5%. Creating a genotyped reference panel improves accuracy and sample size but is limited by assay conversion failures. Finally, our study suggests that tag SNP density characteristic of first-generation GWAS arrays may be inadequate to maximally extract information with current imputation algorithms. To some extent, these limitations are transient: the growing 1000 Genomes Project resource is sequencing >2,000 diverse samples with both low-pass whole-genome and highcoverage targeted-exon approaches, increasing the accuracy and completeness of the public reference panel. However, our results suggest that fully exploiting this resource rs10757282 and the reported SNP from GWAS, rs10811661, define haplotypes with three levels of risk (risk, protective and neutral) for type 2 diabetes. Signal for each SNP (represented as -log 10 P value) versus genomic position. Size of the diamond for each SNP represents the linkage disequilibrium (measured as r 2 ) between that SNP and the original GWAS SNP (rs10811661 for type 2 diabetes and rs4977574 for myocardial infarction). Recombination rate was estimated from HapMap II.
l e t t e r S for imputation may require increasing tag density in GWAS disease samples and/or improved algorithms for imputation. Finally, in this study we did not find evidence for stronger association at chromosome 9p21 to SNPs in moderate linkage disequilibrium with the initial tag SNPs. Although the maximum achievable association signal for lower-frequency variants was limited by our sample size, we did not observe lower-frequency variants with effect sizes that could individually explain the common variant associations. We did, however, identify additional common variants in linkage disequilibrium with the SNPs with the strongest GWAS signals that might underlie each association. Enumeration of all variants at 9p21 that might explain each association signal will be needed as a foundation for systematic functional studies that aim to understand how different noncoding variants in this single genomic interval can lead to such varied and clinically relevant phenotypic associations.
MetHOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
ONLINe MetHOdS
Targeted resequencing. Six regions associated with type 2 diabetes were selected for targeted resequencing (Supplementary Table 1) . Because the goal of this study to was to identify additional SNPs that might explain the initial GWAS signal, region boundaries were selected to encompass all SNPs showing detectable linkage disequilibrium (r 2 ≥ 0.2) to the type 2 diabetes-associated SNP with the most significant P value. DNA was captured for sequencing by long-range PCR with 2-to 5-kb amplicons or by hybrid selection using 170-base pair (bp) baits tiled across the region on an Agilent microarray 26 . All sequencing was done at the Broad Institute in 2008 using Illumina Genome Analyzers. Runs from PCR-based capture generated 36-bp reads and runs from hybrid selection-based capture generated reads of 46-50 bp. Methods for alignment, quality score adaptation and recalibration and variant calling are described in detail in the Supplementary Note. SNP genotyping and quality control. Genotyping was carried out on the Sequenom MassARRAY iPLEX platform. Quality control filters included >95% genotyping rate, Hardy-Weinberg equilibrium (with P > 0.001) and Mendel error rate < 5%.
Phasing and imputation.
We compared several strategies and publicly available tools for phasing and imputation directly from Illumina sequencing data ( Supplementary Figs. 10 and 11) . Phased haplotypes for all reference panels were created using the PHASE software package (version 2.1) 27,28 . For the genotyped reference panel, trio information was used in phasing (-P1 option). For sequencing reference panels, known phase was specified at HapMap sites (-k option). All other PHASE parameters were assigned default values. Imputation from reference haplotypes was carried out using MACH 22, 23 (Version 1.0.16). We used 100 rounds; all other MACH parameters were assigned default values.
